Your browser is no longer supported. Please, upgrade your browser.
Sorrento Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.95 Insider Own11.22% Shs Outstand280.60M Perf Week-0.69%
Market Cap2.45B Forward P/E5.17 EPS next Y1.68 Insider Trans-0.01% Shs Float255.34M Perf Month26.20%
Income-230.80M PEG- EPS next Q0.36 Inst Own27.30% Short Float19.84% Perf Quarter-8.25%
Sales46.50M P/S52.75 EPS this Y41.00% Inst Trans-2.76% Short Ratio6.87 Perf Half Y23.33%
Book/sh0.82 P/B10.57 EPS next Y5.53% ROA-40.40% Target Price- Perf Year83.30%
Cash/sh0.83 P/C10.39 EPS next 5Y37.00% ROE-124.80% 52W Range4.64 - 19.39 Perf YTD27.03%
Dividend- P/FCF- EPS past 5Y-0.90% ROI-104.90% 52W High-55.29% Beta2.35
Dividend %- Quick Ratio2.70 Sales past 5Y54.20% Gross Margin76.60% 52W Low86.85% ATR0.56
Employees502 Current Ratio2.80 Sales Q/Q85.70% Oper. Margin- RSI (14)56.77 Volatility6.61% 6.30%
OptionableYes Debt/Eq0.44 EPS Q/Q102.40% Profit Margin- Rel Volume0.54 Prev Close8.70
ShortableYes LT Debt/Eq0.35 Earnings- Payout- Avg Volume7.37M Price8.67
Recom2.00 SMA207.43% SMA5012.75% SMA200-1.02% Volume3,960,776 Change-0.34%
Jan-29-21Initiated B. Riley Securities Buy $26
Jan-21-21Initiated Alliance Global Partners Buy $35
Jul-31-20Reiterated H.C. Wainwright Buy $24 → $30
May-26-20Initiated Dawson James Buy $24
Oct-07-19Initiated JMP Securities Mkt Outperform $21
Jun-28-18Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18Reiterated H.C. Wainwright Buy $20 → $30
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
Jun-14-21 06:03PM  
Jun-12-21 06:36AM  
Jun-11-21 04:11PM  
Jun-07-21 04:45PM  
Jun-04-21 03:13PM  
Jun-02-21 04:54PM  
May-20-21 09:00AM  
May-19-21 09:30PM  
May-05-21 08:09AM  
Apr-30-21 07:46AM  
Apr-27-21 02:30PM  
Apr-26-21 02:04PM  
Apr-20-21 09:51AM  
Apr-12-21 08:57AM  
Apr-09-21 10:50PM  
Apr-08-21 06:00AM  
Apr-07-21 06:50PM  
Apr-06-21 10:18AM  
Apr-05-21 09:37AM  
Mar-31-21 09:12AM  
Mar-29-21 01:05PM  
Mar-26-21 03:04PM  
Mar-25-21 03:58PM  
Mar-18-21 09:00AM  
Mar-17-21 01:00AM  
Mar-12-21 10:50PM  
Mar-09-21 09:00AM  
Mar-08-21 07:05AM  
Mar-07-21 10:27PM  
Mar-05-21 01:06AM  
Mar-04-21 12:15PM  
Mar-02-21 04:02PM  
Mar-01-21 12:21PM  
Feb-27-21 09:23AM  
Feb-26-21 10:50PM  
Feb-21-21 06:14AM  
Feb-19-21 04:09PM  
Feb-12-21 09:31AM  
Feb-11-21 06:25AM  
Feb-10-21 03:54PM  
Feb-09-21 05:03PM  
Feb-08-21 03:21PM  
Feb-01-21 04:50PM  
Jan-31-21 05:28PM  
Jan-30-21 08:27AM  
Jan-29-21 12:22PM  
Jan-27-21 01:06PM  
Jan-26-21 07:09PM  
Jan-25-21 04:22PM  
Jan-22-21 06:48AM  
Jan-19-21 05:06PM  
Jan-14-21 08:31PM  
Jan-10-21 05:58PM  
Jan-06-21 05:45PM  
Dec-30-20 12:48PM  
Dec-24-20 10:02AM  
Dec-23-20 02:55PM  
Dec-22-20 06:59PM  
Dec-14-20 12:06AM  
Dec-10-20 09:56AM  
Dec-09-20 01:27PM  
Dec-08-20 08:06PM  
Dec-04-20 04:21PM  
Dec-02-20 07:04AM  
Nov-29-20 08:19PM  
Nov-27-20 11:41AM  
Nov-23-20 04:11PM  
Nov-22-20 02:27PM  
Nov-21-20 01:16PM  
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host diseases. The company also develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. In addition, it engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. Additionally, the company has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Janda KimDirectorApr 12Option Exercise3.501,9006,6504,900Apr 15 06:43 PM
Janda KimDirectorApr 12Sale6.971,90013,2513,000Apr 15 06:43 PM
Followwill DormanDirectorDec 16Sale7.131,0007,1352,130Jan 26 05:24 PM